1312412-87-5

Basic information

• Product Name: 3-BroMo-2,4-dioxo-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 3-BroMo-2,4-dioxo-piperidine-1-carboxylic acid tert-butyl ester;tert-Butyl 3-bromo-2,4-dioxopiperidine-1-carboxylate;tert-butyl 3-bromo-4-hydroxy-2-oxo-5,6-dihydropyridine-1(2H)-carboxylate
• CAS NO: 1312412-87-5
• Molecular Formula: C₁₀H₁₄BrNO₄
• Molecular Weight: 292.12646
• EINECS: -0
• Mol File: 1312412-87-5.mol

Chemical Properties

• Boiling Point: 403.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.521±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.12±0.20(Predicted)
• CAS DataBase Reference: 3-BroMo-2,4-dioxo-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BroMo-2,4-dioxo-piperidine-1-carboxylic acid tert-butyl ester(1312412-87-5)
• EPA Substance Registry System: 3-BroMo-2,4-dioxo-piperidine-1-carboxylic acid tert-butyl ester(1312412-87-5)

Safety Data

• Hazardous Substances Data: 1312412-87-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-2,4-dioxo-piperidine-1-carboxylic acid tert-butyl ester is used as a building block in the synthesis of various pharmaceutical compounds. Its versatile reactivity allows for the creation of different derivatives with potential therapeutic properties.
Used in Chemical Industry:
In the chemical industry, 3-Bromo-2,4-dioxo-piperidine-1-carboxylic acid tert-butyl ester serves as an intermediate in the production of various chemical compounds. Its structural properties and ability to undergo chemical reactions make it a valuable component in the synthesis of specialty chemicals and materials.

Upstream product

• 845267-78-9 tert-butyl 2,4-dioxopiperidine-1-carboxylate 
• 3303-84-2 3-(tert-butyloxycarbonylamino)propionic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1312412-88-6 tert-butyl 2-amino-4-oxo-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate 
• 1035219-96-5 2-bromo-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one 
• 1312414-28-0 5-methyl-2-phenoxymethyl-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one 
• 26493-11-8 2-amino-6,7-dihydrothiazolo[5,4-c]pyridin-4(5H)-one 
• 1446715-66-7 C₁₄H₉FN₂OS 
• 1446715-67-8 C₁₅H₁₂N₂O₂S 
• 1446715-68-9 C₁₅H₁₂N₂OS 
• 1446715-63-4 C₁₄H₉FN₂OS 
• 1446715-64-5 C₁₄H₉ClN₂OS 
• 1446715-65-6 C₁₄H₉FN₂OS 
• 1312412-59-1 LuAF₃₂₁₀₅ 
• 1312412-58-0 2-phenylethynyl-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one 

Relevant articles and documents

ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES

The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and in particular as glycosidase inhibitors.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES

The invention relates to a process for preparing either enantiomer of a compound of formula (I), wherein X, Y and n have the meaning given in claim 1, with high enantiomeric excess (e.e.), by chiral resolution in the presence of a non-racemic, chiral acid.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS

The present invention provides fused thiophene and thiazole derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; in which R1, R2, R3, R4, R5, R6, R7, X1, X2, L, m, n and ring A have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in disease(s) or disorder(s) where there is an advantage in modulating RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the fused thiophene and thiazole derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF

The hedgehog (Hh) signaling pathway is a pathway which regulates patterning, growth and cell migration during embryonic development, but in adulthood is limited to tissue maintenance and repair. Mutational inactivation of the inhibitory pathway components leads to constitutive ligand-independent activation of the Hh signaling pathway, results in cancers such as basal cell carcinoma and medulloblastoma. Ligand-dependent activation of Hh signaling is involved in prostate cancer, pancreatic cancer, breast cancer and blood cancers. Therefore, inhibition of the aberrant Hh signaling represents a promising approach toward novel anticancer therapy. The invention provides novel molecules of formula I that inhibit hedgehog pathway signaling and provides therapeutic applications for the treatment of malignancies (basal cell carcinoma, medulloblastoma, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, blood cancers, mesenchymal cancers, etc.), prevention of tumor regrowth, sensitization of radio-chemo therapies, and other diseases (inflammation, fibrosis and immune disorders).

Fused thiazolyl alkynes as potent mGlu5 receptor positive allosteric modulators

A new series of potent fused thiazole mGlu5 receptor positive allosteric modulators (PAMs) (10, 11 and 27-31) are disclosed and details of the SAR and optimization are described. Optimization of alkynyl thiazole 9 (Lu AF11205) led to the identification of potent fused thiazole analogs 10b, 27a, 28j and 31d. In general, substituted cycloalkyl, aryl and heteroaryl carboxamides, and carbamate analogs are mGlu5 PAMs, whereas smaller alkyl carboxamide, sulfonamide and sulfamide analogs tend to be mGlu5 negative allosteric modulators (NAMs).

Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor

Starting from a singleton chromanone high throughput screening (HTS) hit, we describe a focused medicinal chemistry optimization effort leading to the identification of a novel series of phenoxymethyl-dihydrothiazolopyridone derivatives as selective positive allosteric modulators (PAMs) of the metabotropic glutamate 5 (mGlu5) receptor. These dihydrothiazolopyridones potentiate receptor responses in recombinant systems. In vitro and in vivo drug metabolism and pharmacokinetic (DMPK) evaluation allowed us to select compound 16a for its assessment in a preclinical animal screen of possible antipsychotic activity. 16a was able to reverse amphetamine-induced hyperlocomotion in rats in a dose-dependent manner without showing any significant motor impairment or overt neurological side effects at comparable doses. Evolution of our medicinal chemistry program, structure activity, and properties relationships (SAR and SPR) analysis as well as a detailed profile for optimized mGlu5 receptor PAM 16a are described.

BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.